Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
Skipping Breakfast Related to Higher Cardiovascular Risks
FDA Rejects Dapagliflozin for Type 1 Diabetes
Men Who Have Diabetes Could Be Prone To More Fractures With Stricter Glucose Control
SPECIAL FEATURE
Letter from the Editor
There are many occasions in diabetes history when the experts are either wrong or take too long to recognize what is logically correct. A good example of this is back in the 70’s when the ADA stated, paraphrasing here, “The thought that someone could check their glucose, count their carbs and dose their insulin was ludicrous and would never occur.” Another has to do with the medication metformin, which was approved in most every country in the world in 1957 — but the FDA did not approve it till 1995.
The FDA has just done it again, with their decision to turn down dapagliflozin an indication for use in type 1 diabetes. This week our Intern, Kassey James, Pharm.D. Candidate, LECOM School of Pharmacy, has a special feature on why the FDA rejected the indication and how it goes smack against what tons of prescribers do.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
Newsflash: The FDA has Approved the First Needle-free Rescue Treatment for Severe Hypoglycemia Among Type 2 Diabetes Patients by Eli Lilly and Aptar
This major advancement for the first time provides critical medication with a ready-to-use one-step nasal delivery device which can deliver a powder formulation in an emergency situation quickly and easily versus the traditional injection that may require assembly, including a multistep, time-consuming process of mixing powder and liquid. In 2014, a total of 14.2 million emergency department visits were reported with diabetes among adults aged 18 years or older – including 245,000 for Hypoglycemia, according to the National Diabetes Statistics Report from the Centers for Disease Control and Prevention (CDC). Eli Lilly, Aptar win FDA approval for nasal glucagon powder
TOP STORIES — Diabetes News and Research
Changes in hormones to help control normal blood glucose levels can lead to weight gain and possible heart disease in peoplw who skip breakfast.
The FDA rejected dapagliflozin as a treatment for type 1 diabetes although it was recently approved in Europe and Japan.
Men who have their glucose in control could be facing another challenge as a result.
Did You Know: Mortality Effects Of Consumption of Sugar And Artificially Sweetened Beverages
The consumption of sugar sweetened beverages (SSB) can be a risk factor for many diseases. In epidemiological studies, they were linked to weight gain and a higher risk for type 2 diabetes mellitus, coronary heart disease, and stroke. Very few studies examined the relationship between SSB and mortality. A perspective analysis has established a positive association between baseline intake of added sugar and SSB with CVD mortality. This study was aimed to explore the long-term health effects of consuming SSB, and examined 2 prospective cohort studies. Researchers administered mailed questionnaires biennially to assess lifestyle factors and health status. They assessed diet using a self-administered food frequency questionnaire (FFQ) every 4 years. 80,647 women and 37,716 men were observed. Each FFQ was detailed to assess the consumption of foods and beverages. Nutrients and energy intakes were calculated. Total SSB included all carbonated beverages and non-carbonated beverages excluding fruit juice. Artificially sweetened beverages included low calorie/diet beverages, carbonated beverages and non-carbonated beverages. To incorporate death, international classification of diseases (ICD) codes were used to distinguish between deaths caused by CVD or cancer including breast cancer, lung cancer, and colon cancer. A 7% higher risk of death was associated with an increased serving/day in SSB. CVD mortality was also increased with SSB. Participants who consumed more than 2 servings per day had a 31% higher chance of deaths from CVD. Cancer mortality was also higher. Among women, breast cancer mortality had a positive association with SSB consumption. A 4% lower risk of total mortality is estimated when replacing 1 serving/day of SSB with 1 serving per day of ASB, and a 4% lower risk of cancer mortality.
Malik, Vasanti S., et al. “Long-Term Consumption of Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Mortality in US Adults.” Circulation, vol. 139, no. 18, 2019, pp. 2113–2125.
— Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:
Usif Darwish, PharmD Candidate, Florida A&M University, College of Pharmacy & Pharmaceutical Sciences
Kassey James, Pharm.D. Candidate, LECOM School of Pharmacy
Joel John, Pharm.D. Candidate, Florida A&M University, College of Pharmacy & Pharmaceutical Sciences
Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy
Amber Satz, PharmD Candidate, LECOM School of Pharmacy
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com
About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.